Comparison between external beam radiotherapy (70 Gy/74 Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients

Radiotherapy and Oncology

Volumn 103, Issue 2, 2012, Pages 223-227

  Goldner, Gregor ^a   Pötter, Richard ^a   Battermann, Jan J ^b   Kirisits, Christian ^a   Schmid, Maximilian P ^a   Sljivic, Samir ^a   Van Vulpen, Marco ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Biochemical control; External beam radiotherapy; Permanent interstitial brachytherapy; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERMANENT INTERSTITIAL BRACHYTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE;

AGED; BRACHYTHERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK;

EID: 84860429351     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.01.016     Document Type: Article

References (35)

1. J.J. Battermann I-125 implantation for localized prostate cancer: the Utrecht University experience Radiother Oncol 57 2000 269 272
2. J.J. Battermann, T.A. Boon, and M.A. Moerland Results of permanent prostate brachytherapy, 13 years of experience at a single institution Radiother Oncol 71 2004 23 28
3. K.A. Hinnen, J.J. Battermann, and J.G.H. van Roermund Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 76 2010 1433 1438
4. B.R. Pieters, D.Z. de Back, C.C. Koning, and A.H. Zwinderman Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review Radiother Oncol 93 2009 168 173
5. M.J. Zelefsky, D.A. Kuban, and L.B. Levy Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation Int J Radiat Oncol Biol Phys 67 2007 327 333
6. J.E. Sylvester, J.C. Blasko, P.D. Grimm, R. Meier, and J.A. Malmgren Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience Int J Radiat Oncol Biol Phys 57 2003 944 952
7. G. Goldner, V. Bombosch, and H. Geinitz Moderate risk adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy Strahlenther Onkol 185 2009 94 100
8. G. Goldner, J. Dimopoulos, C. Kirisits, and R. Pötter Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy Strahlenther Onkol 185 2009 438 445
9. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with78 Gy J Clin Oncol 24 2006 1990 1996
10. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
11. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
12. P.A. Kupelian, L. Potters, and D. Khuntia Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer Int J Radiat Oncol Biol Phys 58 2004 25 33
13. C. Salembier, P. Lavagnini, and P. Nickers Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy Radiother Oncol 83 2007 3 10
14. D. Ash, A. Flynn, J. Battermann, P. Lavagnini, and L. Blank ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer Radiother Oncol 57 2000 315 321
15. Leitlinienprogramm Onkologie, S3-Leitlinie Prostatakarzinom, Version 2.0, 1. Aktualisierung 09.2011; < http://www.degro.org/dav/html/leitlinien/LLPCA. pdf >.
16. N.P. Munro, B. Al-Qaisieh, and P. Bownes Outcomes from Gleason 7, intermediate risk localized prostate cancer treated with iodine-125 monotherapy over 10 years Radiother Oncol 96 2010 34 37
17. National Comprehensive Cancer Network Website. < http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp >.
18. D.B. Chism, A.L. Hanlon, E.M. Horwitz, S.J. Feigenberg, and A. Pollack A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy Int J Radiat Oncol Biol Phys 59 2004 380 385
19. R. Nath, L.L. Anderson, and G. Luxton Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM radiation therapy committee task group no. 43 Med Phys 22 1995 209 234
20. ICRU Report 62: prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50) 1999 International Commission on Radiation Units and Measurements Bethesda
21. K.A. Hinnen, M.A. Moerland, and J.J. Battermann Loose seeds versus stranded seeds in I-125 prostate brachytherapy: differences in clinical outcome Radiother Oncol 96 2010 30 33
22. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference Int J Radiat Oncol Biol Phys 65 2006 965 974
23. S. Faria, A.D. Pra, and F. Cury Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone Radiother Oncol 101 2011 486 489
24. S. Nag, D. Beyer, and J. Friedland American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer Int J Radiat Oncol Biol Phys 44 1999 789 799
25. J.M. Cosset, T. Flam, and N. Thiounn Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the paris institut curie/cochin hospital/necker hospital group on 809 patients Int J Radiat Oncol Biol Phys 71 2008 1042 1048
26. A. Al-Mamgani, W. Heemsbergen, P.C. Levendag, and J.V. Lebesque Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial Radiother Oncol 96 2010 13 18
27. Z.A. Alicikus, Y. Yamada, and Z. Zhang Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer Cancer 117 2011 1429 1437
28. G. Goldner, S. Sljivic, and R. Oismueller Prostate cancer radiotherapy in Austria: overview on number of patients, intention to treat and treatment techniques based on the year 2007 Strahlenther Onkol 187 2011 279 283
29. M. Roach 3rd Equations for predicting the pathologic stage of men with localized prostate cancer using the preoperative prostate specific antigen (PSA) and Gleason score J Urol 150 1993 1923 1924
30. M. Roach 3rd, M. DeSilvio, and R. Valicenti Whole-pelvis, ''mini-pelvis", or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial Int J Radiat Oncol Biol Phys 66 2006 647 653
31. M. Roach 3rd, M. DeSilvio, and C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911
32. P. Pommier, S. Chabaud, and J.L. Lagrange Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01 J Clin Oncol 25 2007 5366 5373
33. M. Roach 3rd Predicting pathologic stage, nomograms, and clinical judgment: don't miss the forest for the trees! Int J Radiat Oncol Biol Phys 73 2009 325 326
34. M. Roach 3rd Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials J Clin Oncol 26 2008 3816 3817 [author reply 3817-8]
35. P.L. Nguyen, and A.V. D'Amico Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials J Clin Oncol 25 2007 5366 5373